The currently available COVID-19 vaccine is thought to be sufficient in protecting against SARSCoV-2 infection, whilst the constant mutations of SARS-CoV-2 and the failure of the vaccine mto evoke protective mucosal immunity have remained problems. This condition has brought forward the idea of targeting nucleocapsid (N) protein as a more conserved region of SARS-CoV-2, in addition to the spike…